CK 3368
Latest Information Update: 30 May 2001
Price :
$50 *
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Antihyperlipidaemics
- Mechanism of Action Bile acid binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 30 Jun 1998 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)
- 12 Jul 1995 New profile